Bristol Myers Squibb saw a positive improvement to its Relative Strength (RS) Rating on Thursday, with an upgrade from 62 to 72.
This exclusive rating from Investor's Business Daily identifies market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price movement over the last 52 weeks holds up against all the other stocks in our database.
Decades of market research reveals that the best-performing stocks often have an RS Rating of at least 80 in the early stages of their moves. See if Bristol Myers Squibb can continue to show renewed price strength and hit that benchmark.
How To Invest In Stocks In Both Bull And Bear Markets
Bristol Myers Squibb is not currently near a potential buying area. See if the stock goes on to form a sound pattern that could ignite a new run.
Earnings grew 18% last quarter, up from -7% in the prior report. Revenue also increased, from 5% to 9%. The next quarterly results are expected on or around Oct. 31.
Bristol Myers Squibb holds the No. 1 rank among its peers in the Medical-Ethical Drugs industry group. Novartis ADR and Phibro Animal Health are also among the group's highest-rated stocks.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Price Performance?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
